Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
9 studies found for:    "Hemispherx Biopharma" [Exact]
Show Display Options
Rank Status Study
1 Terminated Safety Study of FluMist With and Without Ampligen
Condition: Influenza, Human
Interventions: Drug: FluMist + Poly I:Poly C12U 50 ug;   Drug: FluMist + Poly I:Poly C12U 200 ug;   Drug: FluMist + Poly I:Poly C12U 500 ug;   Drug: FluMist + Poly I:Poly C12U 1250 ug;   Drug: FluMist + Placebo
2 Terminated A Randomized, Dose-ranging Study of Alferon LDO in Asymptomatic HIV+ Subjects
Condition: HIV Infections
Intervention: Drug: Alferon LDO
3 Completed Study of Alferon® LDO (Low Dose Oral) in Normal Volunteers
Condition: Severe Acute Respiratory Syndrome
Intervention: Drug: Alferon LDO
4 Active, not recruiting Ampligen in Chronic Fatigue Syndrome
Condition: Chronic Fatigue Syndrome
Intervention: Drug: Poly I: Poly C12U (Rintatolimod)
5 Completed The Study of the Safety and Efficacy of Ampligen in Chronic Fatigue Syndrome
Conditions: Chronic Fatigue Syndrome;   Myalgic Encephalomyelitis
Intervention: Drug: Ampligen
6 Completed The Role of Ampligen in Strategic Therapeutic Intervention (STI) of HAART
Conditions: HIV Seropositivity;   HIV Infection
Intervention: Drug: poly I-poly C12U
7 Terminated Safety and Efficacy of Ampligen in the Treatment of HIV Patients Failing HAART
Conditions: HIV Seropositivity;   HIV Infection
Intervention: Drug: poly I-poly C12U
8 Recruiting Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer
Conditions: Colorectal Cancer;   Colorectal Carcinoma;   Colorectal Tumors;   Neoplasms, Colorectal
Intervention: Drug: Chemokine modulatory regimen
9 Recruiting Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
Conditions: Cancer of Ovary;   Cancer of the Ovary;   Neoplasms, Ovarian;   Ovarian Cancer;   Ovary Cancer;   Ovary Neoplasms
Interventions: Biological: Cisplatin + celecoxib + DC vaccine;   Biological: Cisplatin + CKM + Celecoxib + DC Vaccine

Study has passed its completion date and status has not been verified in more than two years.